Since it is conceivable that the alveolar space is the site of GM-CSF signal disruption, with the impairment of surfactant catabolism in autoimmune PAP, then it is reasonable to propose that local GM-CSF supplementation would result in better treatment outcome. The gene discussed is CSF2; the disease is Autoimmunity.